SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

IntelGenx Technologies Corp. (IGXT)

Add IGXT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator GaryJPalys
Search This Board:
Last Post: 4/20/2015 7:17:06 PM - Followers: 182 - Board type: Free - Posts Today: 0

IntelGenx Technologies Corp

Listing Exchanges: OTCQX as IGXT and Toronto Venture Exchange: IGX.V

Current partners include, Edgemont Pharma, Pacific Therapeutics, Dava Pharmaceuticals, RedHill Biopharma, and PAR Pharmaceuticals. We are in discussions with other potential partners for some of our other products.

Our unique proprietary platform delivery technologies offer many benefits to our partners including:
Broad range of delivery profiles
Convenient and versatile products
High quality products

Business Strategy
Our business strategy is to apply our drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with
strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. 

Because we are developing improved formulations of currently marketed therapeutics, our products typically require fewer clinical trials to generate the safety and
efficacy data needed to achieve regulatory approval than drug formulations that have not been previously marketed. As a result, we believe we can accelerate
development and reduce risk compared to traditional pharmaceutical and biotechnology companies. 

Using the 505(b)(2) approach to obtain FDA approval, our products have the possibility of obtaining  three years of market exclusivity.


IntelGenx (IGX / IGXT) Announces Commercial Launch of Forfivo XL(TM) in USA - Viral News

(Click the link below to watch video)

    Forfivotm XL Launch Video


(Click on picture below to go to website)


Friday, October 5, 2012

Withdrawal of Teva's Budeprion XL 300 from the US market should benefit IntelGenx Technologies

USFDA has asked Teva to wihdraw - Budeprion XL 300 from the US.
  According to USFDA, Budeprion XL 300 is no bioequivalent to Welbutrin XL 300.
  It has been found that Budeprion XL 300 releases the active ingredient faster than the original drug Welbutrin XL 300.
The USFDA reviewed the Budeprion XL, after several patients complained 
about head aches, anxiety and insomnia.

We think the withdrawal can be positive for IntelGenx
which is preparing to launchForfivo ( bupropion extended release 450mg)
and should help the launch trajectory for Forfivo. 
Forfivo will be marketed by Edgemont pharmaceuticals in the US.
Edgemont focuses exclusively on launching specialty drugs aimed at the neuropsychiatry sector,
and has one drug on the market - high-dose fluoxetine (Prozac).

Forfivo is the only single tablet that is formulated to deliver a dose of 450mg.
Until now, those patients who need to take the highest dose (450mg)
of bupropion XL need to take multiple tablets of lower-strength doses as there.

Market Opportunity

In 2011, total branded and generic sales of extended-release bupropion
totaled $745 million, of which 
roughly 20% was for the highest dose (450mg).


IntelGenX Corporate Presentation January 2015

Click on the image below
January, 2015





March 12th, 2012 -   Cleland Fund comments regarding their investment insight for IGXT: 

March 12, 2012 -   BluMont Capital Corporation - Northern Rivers Funds - 70 University Avenue - Suite 1200, PO Box 16 - Toronto, ON M5J 2M4 - Canada - Tel: 416.597.1226 - Fax: 416.597.8926

The Northern Rivers Innovation RSP Fund ("the Innovation Fund" or "the Fund") Dear Partners and Friends: Let's go through the major holdings…(Below is just the IGXT portion)

INTELGENX: FDA approval for their 1st drug in November + a commercialization partner for that drug + a deal with Par Pharmaceuticals = lower share price??? This is a completely irrational situation, making IntelGenx a table pounder. As of the close on March 7, the stock is LOWER than it was before CPI-300 (IntelGenx' antidepressant) received FDA approval; LOWER than it was before the deal with Par Pharmaceutical; and LOWER than it was before the announcement of its commercialization partner for CPI-300. I would argue that at $0.55 or lower, the only thing an investor is paying for is CPI-300, meaning that you are getting the entire thin-film delivery platform and 9 drug pipelines for FREE. Notably, there are only a handful of thin-film companies out there, and IntelGenx is one of only two that are publicly traded (that I am aware of). As thin-films become more recognized for their value to big pharma over the coming years, the scarcity value of thin-film platforms will ultimately result in IntelGenx' thin-film platform and pipeline receiving a premium valuation; right now, there is NO value. Ridiculous. I have put my money where my mouth is recently, and bought shares in the open market for the second of the two funds I run. To a certain degree, however, I understand what has happened: there was (unbeknownst to me or management) a scummy promote on IntelGenx last summer, in which CPI-300 was hyped as a billion dollar drug. Anyone who knows anything about CPI-300 and its market knows that that is complete crap. In fact, CPI-300 is the smallest revenue potential drug within IntelGenx' pipeline, with peak revenue to Intelgenx' commercialization partner maybe in the $60-$100million range. This means that reality has been a big let-down to those who bought into the billion dollar dream. But the fact is that the commercialization deal and FDA approval for CPI-300 do two very important things for IntelGenx: 1) Getting CPI-300 approved by the FDA provided concrete illustration that IntelGenx has the skill set to negotiate the 505b2 pathway to drug approval, which involves both dealing with the FDA and dealing with the court system. For me, that validation will ultimately lower the discount rate that is applied to the rest of IntelGenx' pipeline. 2) The upfront, milestone and royalty payments from the commercialization deal for CPI-300 arguably cover all of IntelGenx' development costs for its pipeline of thin-film 505b2 drugs. If this sounds far-fetched, recall that the 505b2 pathway to drug approval is dramatically different than the conventional PhaseI-II-III pathway, because IntelGenx is simply moving existing, already-FDA-approved drugs onto a different delivery platform. i.e., IntelGenx is working on projects such as moving Cialis and a migraine drug onto a thin-film platform. It is a cheap, and extremely low-risk pathway to getting a drug to market. The CPI-300 deal with Edgemont Pharmaceuticals: a source of disappointment for the market; a source of confidence for me On February 14, IntelGenx announced a commercial license agreement for CPI-300 with Edgemont Pharmaceuticals. The deal provided for $1M upfront for IntelGenx and a series of milestones that could reach $28.5M over the life of the agreement. According to the company up to $4M of these milestones are achievable at the product launch or shortly thereafter. IntelGenx is also entitled to a double digit royalty on net product sales. The market reaction thus far to the deal has been negative. It seems many people were perhaps speculating on a more prominent partner and/or better economics in the deal. However, I think the markets have misinterpreted the quality of the deal, I think in part due to misjudging Edgemont but also misunderstanding what CPI-300 means to IntelGenx. On the former, Edgemont is a smaller private company that has very little visibility to people outside the industry. But a closer inspection reveals a company with a sales and marketing focus on neurology, a CEO who formerly ran Novartis' CNS business in the US, and a Board populated with people from some of the most successful U.S. specialty pharma companies of the past 15 years. This last point is one of the nuances that the markets really seem to have missed. Two of the Edgemont Board members are former Kos Pharmaceuticals (formerly Nasdaq: KOSP) executives who now work for a private equity firm called Vatera Capital. For anyone who hasn't heard of Kos, they were arguably the most successful specialty pharma company in the U.S. in the past 15 years. They created a market for a prescription vitamin called Niaspan, which paved the way for future prescription vitamin and omega-3 companies like Reliant, Amarin and Neptune/Acasti. Kos was eventually bought by Abbott for $3.7B, and one of the founders Michael Jaharis took his money (he is estimated now to be worth $1.9B) and formed Vatera Capital to invest in businesses like Edgemont. So Vatera's investment in Edgemont gives me tremendous confidence that IntelGenx has landed a great partner who has the marketing savvy and financial backing to extract the most value out of CPI-300. That leads me to my second point regarding the significance of this deal to IntelGenx: In my opinion CPI-300 will provide IntelGenx the financial platform to aggressively accelerate and expand its pharmaceutical thin-film business. Thin-films are the big opportunity in IntelGenx' portfolio. Whether it is drugs for erectile dysfunction, insomnia or migraine, each of these products represent bigger opportunities for IntelGenx than CPI-300. With Reckitt Benckiser's suboxone film (one of only two FDA approved thin films) apparently trending toward $1B in annual sales, it is clear that the market and FDA are receptive to this new delivery system. Fortunately IntelGenx has a number of products through pilot human studies and one product (migraine) due to enter pivotal studies shortly, so they would appear to be well positioned with a number of nearer term thin-film projects. With all this in mind, I believe that Edgemont and CPI-300 provide a means to a much more lucrative end, that being IntelGenx becoming the world leader in the growing area of thin film drug delivery and development.


                                                                                                                                                                                  The following info is now based on IGXT's own SEC filings

Industry: Bio-technology

Market Capitalization: 41.89 Million 

Issued Shares: 63.1 Million

Fully Diluted Shares: 72 Million

Float Shares: 56.9 Million

Insider and Institutional Ownership: 18% 


Latest News

  •                                                                                                                                                                                                                                                                        (Click on Date for link to news article)

Intelgenx Provides Update on Sales of Forfivo XL(R)


Intelgenx Announces Management Changes


Intelgenx Announces Equity Analyst Coverage by H.C. Wainwright


Intelgenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014 for Anti-Migraine VersaFilm(TM) Product


Intelgenx Reports Q1 2014 results and provides corporate developement update


Intelgenx Announces government of canada funding for cNS VersaFilm(TM) project


Intelgenx and Redhill Biopharma Announce Commencement of a Bioavailability Study with Anti-Migraine VersaFilm(TM) Product to support european marketing application planned for q3/2014



and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product


Intelgenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology


Intelgenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines


Intelgenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm


IntelGenx Announces Additional Developement and Commercialization with Par for Two More Products


IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint


IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL™


IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights


Time To Revalue IntelGenx- 2 More Products Being Reviewed By The FDA For Approval



Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction


Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland


IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product


IntelGenx Reports Q1, 2013 Results and Provides Operational Update


IntelGenx secures leadership Succession


IntelGenx submits New Drug Application for Anti-Migraine VersaFilm(TM)


IntelGenx Announces Commercial Launch of Forfivo XL(TM) in USA


  IntelGenx Reports Second Quarter 2012 Results and Highlights Recent Developments


IGXT Website:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IGXT News: Post-effective Amendment to Registration Statement (pos Am) 04/20/2015 05:26:05 PM
IGXT News: Statement of Changes in Beneficial Ownership (4) 04/20/2015 04:04:54 PM
IGXT News: Statement of Changes in Beneficial Ownership (4) 04/20/2015 04:04:54 PM
IGXT News: Current Report Filing (8-k) 04/16/2015 08:04:49 AM
IGXT News: Initial Statement of Beneficial Ownership (3) 04/10/2015 06:31:09 PM
News News Alert: Post-effective Amendment to Registration Statement (pos Am) 04/20/2015 05:26:05 PM
#11096  Sticky Note IntelGenx Announces Analyst Coverage Initiated by Singular Research GaryJPalys 04/16/15 07:44:03 PM
#11100   Tax rates here in Quebec are the highest Tasso9 04/20/15 07:17:06 PM
#11099   Gary, do you think that could be holding mjg24718 04/20/15 06:54:20 PM
#11098   WOW! Just noticed that Roadmap Capital (Hugh Cleland) GaryJPalys 04/20/15 04:16:35 PM
#11097   That's strange... On April 10th. 2015 Ingrid Zerbe GaryJPalys 04/20/15 04:07:26 PM
#11096   IntelGenx Announces Analyst Coverage Initiated by Singular Research GaryJPalys 04/16/15 07:44:03 PM
#11095   Thank you Gary! I appreciate you responding back. Want2BMillionaire 04/14/15 06:52:31 PM
#11094   2016 is what was said in the conference call... GaryJPalys 04/14/15 06:14:20 PM
#11093   Does anyone know when IGXT will hear about Want2BMillionaire 04/13/15 11:44:13 AM
#11092   IntelGenx (TSXV: IGX) (OTCQX: IGXT) Founder, Stockmountie 04/10/15 09:35:34 AM
#11091   That might give Intelgenx a good move today! GaryJPalys 04/10/15 05:05:13 AM
#11090   New video out of Horst on Fox Business News mjg24718 04/09/15 08:29:08 PM
#11089   IntelGenx (TSXV: IGX) (OTCQX: IGXT) Grants Stock Options Stockmountie 04/02/15 12:17:30 PM
#11088   from 10K: "Maximum Total Debt to Tangible Net chemist72 03/31/15 10:31:41 AM
#11087   IntelGenx (TSXV: IGX) (OTCQX: IGXT) Reports 2014 Annual Stockmountie 03/31/15 08:12:16 AM
#11086   Just as they always release a PR about GaryJPalys 03/24/15 03:41:11 PM
#11085   I had to go back and check... You're GaryJPalys 03/24/15 03:03:20 PM
#11084   I think it is worth noting they usually killers_420 03/24/15 07:49:50 AM
#11083   Very strange that it was up over 14% GaryJPalys 03/24/15 04:57:32 AM
#11082   IntelGenx (TSXV: IGX) (OTCQX: IGXT) to Report 2014 Stockmountie 03/23/15 08:07:32 AM
#11081   IGXT was already involved with Par when they GaryJPalys 03/13/15 03:29:23 PM
#11080   another pr release RRM railroadman 03/13/15 03:28:11 PM
#11079   Out this am Par to got public. Any railroadman 03/13/15 03:22:27 PM
#11078   Looks like Roadmap Capital sold off another 500,000 shares... GaryJPalys 03/10/15 04:25:06 AM
#11077   I hope it's deep pockets and they put jevansac 03/03/15 02:42:23 PM
#11076   Way above normal trading volume!!! Any thoughts to railroadman 03/02/15 03:59:52 PM
#11075   Nice move for IGXT today; RSI > 85% chemist72 03/02/15 02:05:53 PM
#11074   I have been holding IGXT for over a havnagoodtime 03/02/15 01:34:17 PM
#11073   Ok, I just read the Seeking Alpha transcript GaryJPalys 03/02/15 05:13:34 AM
#11072   Good evening Gary, railroadman 03/01/15 07:19:24 PM
#11071   Where did you see that? Do you have GaryJPalys 03/01/15 03:39:08 PM
#11070   Gary, any insights to Redhill shedding the 103 migraine railroadman 03/01/15 07:31:37 AM
#11069   Stock is moving up quietly. Maybe some good railroadman 02/28/15 05:34:13 AM
#11068   Royalty % for Forfivo - does anyone know killers_420 02/25/15 03:30:59 PM
#11067   Edgemont is due to give some of the ezey 02/25/15 11:52:43 AM
#11066   That's a very good possibility! GaryJPalys 02/23/15 05:37:27 PM
#11065   IGXT getting close to profitability?? chemist72 02/23/15 10:10:50 AM
#11064   IntelGenx (TSXV:IGX) (OTCQX:IGXT) Provides Update on Sales Stockmountie 02/23/15 08:08:38 AM
#11063   Thanks, duly noted and intro box updated! GaryJPalys 02/17/15 09:02:47 AM
#11062   Thanks Gary, railroadman 02/17/15 06:36:19 AM
#11061   There were 2 SEC filings, both Form SC GaryJPalys 02/15/15 10:12:16 PM
#11060   Should be around 2nd. week of March... GaryJPalys 02/02/15 05:03:55 PM
#11059   When will the quarter numbers to be released? RRM railroadman 02/02/15 08:07:50 AM
#11058   2 year weekly looking sweet. jevansac 01/26/15 07:06:46 PM
#11057   Yeah, but holding the fifties well. That's sort jevansac 01/22/15 08:28:04 PM
#11056   Not a whole lot of excitement going on... GaryJPalys 01/22/15 05:10:03 PM
#11055   2½ hours into the market and 1,150 shares GaryJPalys 01/15/15 12:03:57 PM
#11054   Institutional portfolio adjustment?? chemist72 01/08/15 08:58:57 AM
#11053   Yes, but the question is, why? What is GaryJPalys 01/08/15 05:06:21 AM
#11052   Nice volume today - finally! chemist72 01/06/15 03:39:39 PM
#11051   Someone knows something to make this keep going up. istock oy 01/06/15 12:53:17 PM